607 related articles for article (PubMed ID: 28223379)
1. Mutations in
Haidar G; Clancy CJ; Shields RK; Hao B; Cheng S; Nguyen MH
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223379
[TBL] [Abstract][Full Text] [Related]
2. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
[TBL] [Abstract][Full Text] [Related]
3.
Shields RK; Nguyen MH; Press EG; Chen L; Kreiswirth BN; Clancy CJ
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242667
[TBL] [Abstract][Full Text] [Related]
4. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
5. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
[TBL] [Abstract][Full Text] [Related]
6. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
[TBL] [Abstract][Full Text] [Related]
7. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.
Venditti C; Butera O; Meledandri M; Balice MP; Cocciolillo GC; Fontana C; D'Arezzo S; De Giuli C; Antonini M; Capone A; Messina F; Nisii C; Di Caro A
Clin Microbiol Infect; 2021 Jul; 27(7):1040.e1-1040.e6. PubMed ID: 33775814
[TBL] [Abstract][Full Text] [Related]
9. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
Tsivkovski R; Lomovskaya O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028
[TBL] [Abstract][Full Text] [Related]
10. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
[TBL] [Abstract][Full Text] [Related]
11. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
[TBL] [Abstract][Full Text] [Related]
12. Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.
Humphries RM; Hemarajata P
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396547
[No Abstract] [Full Text] [Related]
13. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.
Hobson CA; Pierrat G; Tenaillon O; Bonacorsi S; Bercot B; Jaouen E; Jacquier H; Birgy A
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0044722. PubMed ID: 35980232
[TBL] [Abstract][Full Text] [Related]
14. Analyses of a Ceftazidime-Avibactam-Resistant
Castanheira M; Arends SJR; Davis AP; Woosley LN; Bhalodi AA; MacVane SH
mSphere; 2018 Sep; 3(5):. PubMed ID: 30258039
[TBL] [Abstract][Full Text] [Related]
15. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2.
Hemarajata P; Humphries RM
J Antimicrob Chemother; 2019 May; 74(5):1241-1243. PubMed ID: 30753572
[TBL] [Abstract][Full Text] [Related]
16. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
Hobson CA; Cointe A; Jacquier H; Choudhury A; Magnan M; Courroux C; Tenaillon O; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2021 Aug; 27(8):1172.e7-1172.e10. PubMed ID: 33915286
[TBL] [Abstract][Full Text] [Related]
18.
Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
[TBL] [Abstract][Full Text] [Related]
19. Exploring avibactam and relebactam inhibition of
Alsenani TA; Viviani SL; Papp-Wallace KM; Bonomo RA; van den Akker F
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0035023. PubMed ID: 37750722
[No Abstract] [Full Text] [Related]
20. Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam.
Alsenani TA; Viviani SL; Kumar V; Taracila MA; Bethel CR; Barnes MD; Papp-Wallace KM; Shields RK; Nguyen MH; Clancy CJ; Bonomo RA; van den Akker F
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0241421. PubMed ID: 35341315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
